Summary.-The effects of one large single dose of 5-fluorouracil (FU) have been compared to the same amount given in divided doses daily over a 3-or 5-day period.
There were marked increases in animal mortality from drug toxicity following fractionated doses of FU compared to one large single dose. Mortality in animals with Tumour 3924A increased from 10% following one large single dose to 600/ for animals given daily fractionated doses for 3 days, and 80o/ for animals given daily fractionated doses for 5 days. Total marrow reserve was measured by the total DNA content of tibial marrow. The nadir of 6 days for loss of total tibial marrow DNA following one large dose of FU was increased to 9 days for both fractionated schedules of FU. The 3-day delay in recovery of the marrow prevented recovery within the time frame necessary for animal survival. The inference from these experimental cancertreatment studies is that daily fractions of chemotherapeutic agents such as FU result in increased morbidity and mortality, without benefit in the control of the solid tumour. The results question the advisability of the clinical practice of initially giving small daily "loading doses" of proliferation-dependent agents such as FU.
These results emphasize the need for more precise information on the temporal relationship between the response and recovery of the host and the response and recovery of the solid tumour. They also emphasize the need for a better clinical understanding of the time sequence of solid-tumour recovery in relation to the time sequence of marrow recovery.
"ALTHOUGH 5-fluorouracil (FU) has been used clinically since 1957, there presently exists a wide divergence in opinion among individual investigators, institutions, and-cooperative groups about the optimal dosage regimen" (Ansfield et al., 1977) . Initial "loading doses" of FU and other proliferation-dependent cancerchemotherapeutic agents are given daily or on alternate days and pushed to the point of mild toxicity. This approach to the clinical management of cancer patients uses, in most instances, host toxicity as the primary guide for the scheduling of the proliferation-dependent chemotherapy agents such as FU. Quantitative assessment of tumour response is often difficult or impossible. It is evident that more precise information on the temporal relationship between the response and recovery of the host and the response and recovery of the tumour is needed for a more rational design of clinical protocols.
Studies (Kovacs et al., 1977 Marrow evaluation.-At various times after injection of 150 mg/kg of FU, groups of 3 rats each were injected i.p. with 50 HCi thymidine-(methyl)-3H (sp. act. 3 Ci/mmol) and the rats killed 1 h later. The marrow was aspirated from the tibia with cold 0-9o NaCl. DNA was extracted by heating at 90°C for 20 min with 5%0 trichloroacetic acid and was measured by the method of Burton (1956) . Calf thymus DNA (Sigma, St. Louis, Mo) was the standard. Radioactivity in the nucleic-acid extracts was measured on a Beckman liquid scintillation spectrophotometer using external standardization, as previously described (Hopkins et al., 1976) .
5-Fluorouracil (FU).-FU (Roche Laboratories, Hoffman-La Roche Inc., Nutley, NJ) prepared in sterile saline was given by i.p. injection between 8.00 and 8.30 a.m. The volume injected was 1 ml. Control animals were injected with saline.
RESULTS
The time sequence of the effects of FU on the marrow reserve, peripheral blood and animal survival after single or "split doses" of 150 mg/kg FU is given in Fig. l . It has been found in well-defined "split dose" animal survival studies that rats recover rapidly and reach 10000 survival levels when the second dose of FU is given 10-11 days after the first. All animals die when the second dose of FU is given 3-4 days after the first. Rapid recovery occurs, so that all animals survive, if the second dose is given 9-10 days after the first (Fig. 1) The recovery of the marrow reserve, as measured bv the total DNA content of tibial marrow, in all 3 groups is shown in Fig. 3 . The nadir for marrow depression following the large single dose of FU (150 mg/kg) occurs at Day 6, which is only 200% of control values ( Fig. 3 ; see also of control values. The recovery of the total marrow reserve has increased to 4000 of control values by this time (9 days) in the single-dose group. It returns to control values 4 days later, 13 days after the initiation of treatment. The marrow reserve of the 2 fractionated-dose groups had only returned to -500 of control values. All animals in the group given 30 mg/kg in 5 daily doses died before 17 days, which accounts for the lack of information in this group beyond 13 days.
Animal-survival studies in the single and both fractionated-dose groups with 3924A tumours are shown in Fig. 4 (see Table II Extensive studies on the effects of single and "split doses" of FU over a number of years have shown that almost all animals which died from the toxic effects of FU were dead 1-2 weeks after initiation of treatment. The longest time recorded for death from toxicity was 18 days. The study was extended for 1 week after this to ensure that accurate mortality statistics on the single and fractionated treated groups would be obtained. Tumour line H-4-1I-E metastasizes to the regional lymph nodes and lungs. The animal-survival studies for the control and treated groups is shown in Fig. 5 . The mean survival time for untreated tumour-bearing rats was 2141±1*9 days after the initiation of treatment. The tumours reached an average volume of 19,700±3,100 mm3 22 days after initiation of treatment. The mean survival time for the group given one 150 mg/kg dose of F U was 18-6 i 2 2 days. The mean survival time was 15 0±3-2 days when the FU was given 50 mg/kg daily for 3 days. There was a major reduction in survival time to 7 9±1 9 days when the FU was given at 30 mg/kg daily for 5 days (see Table II ).
The effect of FU after the single and fractionated doses on tumour growth in 3924A is shown in Fig. 6 . There is growth delay for 9-l 0 days in all 3 groups.
Tumour volume was 25% of control values on Day 7 after initiation of treatment with the large single dose of FU (Table II) . Tumour volume was 2100 of control values after the fractionated dose of 50 mg/kg given daily for 3 days and 36%
of control values after the fractionated dose of 30 mg/kg daily for 5 days. The values for all 3 groups were similar 15 days after the initiation of treatment. They were 23%, 27% and 25% respectively for the large single dose, the fractionated dose for 3 days and the fractionated dose for 5 days. Tumour-volume reduction was compared in the treated groups when the growth rates of all 3 had returned to rates comparable to those in the controls. The mean tumour volume in the group given one large dose of FU was 3400 of control 22 days after the initiation of treatment. The group given 50 mg/kg (Table II) .
DISCUSSION
It was found in previous studies in this series that the total DNA of the tibial marrow decreased to minimal values of 100 of control 3-6 days after a large single dose of FU (150 mg/kg) in both normal and tumour-bearing rats (Hopkins et al., 1976) . These initial findings have been confirmed in this study.
The major difference in the depression of the total marrow DNA after the single dose and fractionated doses of 3-and 5-day periods is in its duration. The nadir for the marrow depression following the 3-and 5-fraction schedules is increased from 6 days for the single dose to 9 days for the fractionated doses. These results also indicate that peripheral white-cell counts, the major clinical indicator for drug toxicity, underestimate the depression of marrow during cancer chemotherapy. Fractionation over the 3-or 5-day period prevents marrow recovery within the time necessary for animal survival. This delay in recovery increased the mortality rates from 10% in the large single-dose FU group to 60% for the 3 daily fractionated groups and 80% for the 5 The in vitro studies by Wolberg and Ansfield (1971) (Looney, et al., 1976b, c) . In these experiments, the marrow recovery time after a single 50 mg/kg dose of FU is 7-8 days. Increasing the dose to 100 or 150 mg/kg prolongs the marrow recovery time to 10-11 days. Thus, one third the FU dose (50 mg/kg) requires two thirds the recovery time for dose 150 mg/kg (Hopkins et al., 1976) .
We have other studies which show that the maximum rate of change of tumour volume occurs shortly after the recovery of the host from the effects of FU. The growth rates of both tumour lines return to rates comparable to controls 11-12 days after treatment with FU. This is also the time of recovery of the marrow for the large single dose of FU. Sequential therapy every 11-12 days with FU permits the optimum sequential utilization of FU for control of tumour growth following host recovery from the previous treatment series.
